DPHARMA logo

Duopharma Biotech Berhad Stock Price

KLSE:DPHARMA Community·RM 1.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

DPHARMA Share Price Performance

RM 1.27
-0.02 (-1.55%)
RM 1.68
Fair Value
RM 1.27
-0.02 (-1.55%)
24.4% undervalued intrinsic discount
RM 1.68
Fair Value
Price RM 1.27
Haha94 RM 1.68

DPHARMA Community Narratives

Haha94·
Fair Value RM 1.68 24.4% undervalued intrinsic discount

Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition

1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Trending Discussion

Updated Narratives

DPHARMA logo

Anticipate Expansion in Duopharma Biotech as Leadership Prepares for Transition

Fair Value: RM 1.68 24.4% undervalued intrinsic discount
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with solid track record.

1 Risk
5 Rewards

Duopharma Biotech Berhad Key Details

RM 900.7m

Revenue

RM 558.1m

Cost of Revenue

RM 342.6m

Gross Profit

RM 259.1m

Other Expenses

RM 83.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.087
38.04%
9.27%
66.0%
View Full Analysis

About DPHARMA

Founded
1978
Employees
1957
CEO
Wan Bin Wan Abdul Majid
WebsiteView website
duopharmabiotech.com

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, including diabetes, cancer, cardiovascular, renal, and other diseases. The company’s product portfolio includes covasc, crystorvas, and vytocor; lebreta, and krabeva; and unihepa, erysaa, bi-haemosol, and haemosol. In addition, it offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, IRORO Nutreatment, and Uphamol brands. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is based in Klang, Malaysia.

Recent DPHARMA News & Updates

Recent updates

No updates